Diabetes mellitus affects approximately 16 million Americans (15, 29) and the cardiovascular complications associated with the disease are the leading cause of the morbidity and mortality among patients (1). The presence of diabetes increases cardiovascular disease risk 2 to 6-fold over that of normal healthy adults (2, 5, 27, 30) , with 40% of type 2 diabetics presenting with concurrent hypertension at the time of diagnosis (54) . This early onset of hypertension suggests that cardiovascular complications may precede the onset of overt diabetes and result from a long-term impaired glucose tolerance and hyperinsulinemia (28) . Alterations in vasoconstrictor responses during this prediabetic state may have profound implications for both the development of cardiovascular complications and the progression of subclinical glucose intolerance to overt type 2 diabetes.
The skeletal muscle is the site of the largest percentage of glucose removal from the blood under insulin stimulated conditions (55) , with the rate of clearance primarily determined by the blood flow delivered to the tissue (3, 7) . Capillary perfusion is determined by the pressure gradient across a capillary bed, which is itself a function of blood flow and precapillary resistance determined primarily at the level of first-, secondand third-order arterioles (26, 36, 53) .Therefore, tone of this resistance vasculature will determine the magnitude of capillary perfusion and consequently glucose utilization in skeletal muscle (2, 3) . In addition, the skeletal muscle microvasculature is a primary determinant of peripheral vascular resistance (12) , so alterations in the responsiveness of the skeletal muscle resistance vasculature to vasoconstrictor agonists may have profound implications for the development and progression of glucose intolerance and hypertension.
Despite the critical role of skeletal muscle blood flow in the regulation of glucose uptake, there is a paucity of data describing alterations in skeletal muscle vasoreactivity in type 2 diabetes. A number of studies have described altered vasomotor responses in the skeletal muscle vasculature of the obese Zucker fatty rat (OZR) (19-24, 40, 46, 52) , a model of the metabolic syndrome. However, unlike the Zucker diabetic fatty (ZDF) rat, the OZR model does not experience a clearly delineated decline in pancreatic function and thus remains hyperinsulinemic throughout most of its lifespan. The ZDF rat was chosen for the present study because it has been shown to initially develop peripheral insulin resistance followed by frank type 2 diabetes at predictable ages (17, 32) .
Moreover, these rats display many of the same conditions as pre-diabetes and type 2 diabetes in humans, such as obesity (6) , hypertension (32) and abnormal blood lipid profiles (6, 8, 17, 49, 50) , making it a clinically relevant model. Furthermore, although changes in function of large arterial rings (9, 48) , intestinal (4), coronary and mesenteric arteries and arterioles (41) have been described during the progression of type 2 diabetes, a similar examination of the skeletal muscle vasculature is lacking. Therefore, the purposes of the present study were to determine whether: 1) there is an increased responsiveness of skeletal muscle arterioles to vasoconstrictor agonists during the natural progression of type 2 diabetes and if they are associated with elevations in mean arterial pressure (MAP), 2) alterations in arterial stiffness contribute to these putative increases in tone, 3) impairment of endothelium-dependent and independent vasodilation occurs during the progression of type 2 diabetes, and 4) the nitric oxide signaling pathway contributes to alterations in vasoconstrictor and endothelium-dependent vasodilator responses. 7 morning electronically averaged MAP was recorded during conscious standing in the cage as previously performed (11). Following blood pressure measurement, blood was collected via the carotid catheter for assessment of plasma glucose and insulin content.
The rat was then euthanized via exsanguination while under anesthesia and the gastrocnemius-plantaris-soleus muscle complex was carefully excised from each hindlimb.
Following excision, the muscle complex was placed in cold (4º C) physiological saline solution (PSS) that contained 145.0 mM NaCl, 4.7 mM KCl, 2.0 mM CaCl 2 , 1.17 mM MgSO 4 , 1.2 mM NaH 2 PO 4 , 5.0 mM glucose, 2.0 mM pyruvate, 0.02 mM EDTA, 3.0 mM MOPS buffer and 1 g/100 ml bovine serum albumin, pH 7.4. Gastrocnemius muscle first-order (1A) arterioles were isolated with the aid of a dissecting microscope (Olympus SVH10) as previously described (37, 38) . After cannulation, the chambers were transferred to the stage of an inverted microscope (Olympus IX70) equipped with a video camera (Panasonic BP310), video caliper (Microcirculation Research Institute), and data acquisition system (MacLab/Macintosh) for recording of luminal diameter. Arterioles were initially pressurized to 44 mmHg with two independent hydrostatic pressure reservoirs. Leaks were detected by pressurizing the vessel and then closing the reservoirs to verify that diameter remained constant. Arterioles that exhibited leaks were discarded.
Arterioles free of leaks were warmed to 37º C and allowed to develop initial spontaneous tone during a 30-60 min equilibration period. ET-1 in the prediabetic condition. Therefore, we sought to determine whether altered mechanical properties of the vessel wall and subsequent alterations in stiffness contribute to these increases in vasoconstrictor responses. To do so, both the active-(myogenic vasoconstriction) and passive pressure-diameter relations (0-110 mmHg) were determined. Medial wall thickness, circumferential stretch and stress, and incremental stiffness were calculated from the passive relations as previously described (38) .
Because both NE and ET-1 can stimulate production and release of the To determine whether the decreased NOS signaling is related to diminished expression of endothelial NOS (eNOS) or superoxide dismutase (SOD), relative differences in eNOS and SOD-1 protein content were assessed in gastrocnemius 1A
arterioles by Western blot as described previously (31) . eNOS protein content was evaluated with a monoclonal antibody (1:1600; catalog no. N30020, BD Biosciences), and SOD-1 protein content was assessed with a polyclonal antibody (1:1600; catalog no. SOD-100, Stressgen). Immunoblots were evaluated by enhanced chemiluminescence (ECL, Amersham) and densitometry by using NIH Image Software (National Institutes of Health, Bethesda, MD). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal standard to control for small differences in protein loading. GAPDH protein content was assessed with a monoclonal antibody (1:10,000, catalog no. MAB374, Chemicon). The data were normalized to GAPDH expression to account for differences in protein loading.
Stock solutions of drugs were prepared in distilled water and frozen. Fresh dilutions of these stocks were prepared daily. All drugs were purchased from Sigma Chemical (St. Louis, MO).
Data Presentation and Analysis. The development of spontaneous tone was expressed as the percent vasoconstriction relative to maximal diameter, and was calculated as previously described (14, [37] [38] [39] . Vasoconstrictor responses to NE, KCl and ET-1 were expressed as a percent change from baseline diameter as previously described (14, 38) . Vasodilator responses were recorded as actual diameters and subsequently expressed as a percent of maximal vasodilation (37) (38) (39) .
Two-way repeated measures ANOVA was used to detect differences between (control vs. pre-diabetic or diabetic) and within (drug concentration or pressure level)
factors. The agonist concentration that produced 50% of the maximal vasoconstrictor or vasodilator response was designated EC 50 or IC 50 , respectively. All EC 50 and IC 50 values were converted to log values for statistical comparison. A one-way ANOVA was used to determine the significance of differences between groups in animal and muscle mass and vessel characteristics. Duncan's multiple range test was used to determine the significance of difference between groups. All data are presented as mean ± SEM.
Significance was set at P Q 0.05.
Results
Animal and Vessel Characteristics. ZDF rats during pre-and short-term diabetes had a greater body mass than age-matched control animals (Control-7, Control-13, respectively), whereas body mass of ZDF rats during long-term diabetes did not differ from age-matched controls (Control-20) (Table 1 ). The ZDF rats became hyperglycemic during short-term diabetes compared to age-matched controls, and this persisted with long-term diabetes (Table 1) . Prediabetic and short-term diabetic rats displayed hyperinsulinemia that subsequently declined in long-term diabetes (Table 1) . MAP was not different between prediabetic and control-7 rats (Table 1) . However, MAP was elevated 15% during short-term diabetes and 19% with long-term diabetes. The gastrocnemius muscle-to-body mass ratio was lower at all time points in the prediabetic and frankly diabetic rats compared to age-matched controls (Table 1) .
Maximal arteriolar lumen diameter determined in vitro from the gastrocnemius muscle was 15% smaller in long-term diabetes, but did not differ at any other time point between groups (Table 1) . Furthermore, spontaneous tone did not differ between the control and pre-diabetic or diabetic rats at any time point.
From histological examination of gastrocnemius muscle arterioles to determine medial wall thickness (Study 2), no differences in maximal diameter between control and pre-diabetic or diabetic rats were evident at any time point (Table 2 ). There was, however, a trend for smaller maximal diameters in arterioles from the long-term diabetic rats (P < 0.1), which is consistent with results obtained from in vitro experiments.
Furthermore, no differences in medial wall thickness were measured between groups at any time point. Both the wall cross-sectional area and wall-to-lumen ratios were higher in arterioles from the prediabetic compared to age-matched control rats (Table 2) . M, P Q 0.1). No differences were found in NE-mediated vasoconstriction in arterioles from short-term diabetic rats (Fig 1B) . Although there was no difference in maximal NE-induced vasoconstriction during long-term diabetes (Fig 1C) , there was a significant dose by group interaction resulting in increased vasoconstriction at given doses of NE (NE [log M]: -8: P Q 0.1, -7: P < 0.05, -6: P Q 0.1) and an increase in arteriolar sensitivity (EC 50 :
To assess the role of the NOS signaling pathway in mediating the enhanced NEmediated vasoconstrictor responses in gastrocnemius muscle arterioles, NE dose responses were repeated following NOS inhibition. These experiments were performed at time points that had previously demonstrated enhanced vasoconstrictor reactivity.
Specifically, we examined the effects of NOS inhibition on NE-mediated vasoconstriction during pre-and long-term diabetes. NOS inhibition increased tone in the gastrocnemius muscle arterioles from the prediabetic and short-term diabetic rat arterioles as well as their age-matched controls ( Table 1 ), indicating that tonic NO bioavailability is similar between the groups. However, L-NAME increased tone in the gastrocnemius muscle arterioles from Control-20 rats, but did not affect tone in their diabetic counterparts, indicating that with long term diabetes there is a decrease in tonic NO bioavailability. Tone following NOS inhibition did not differ between the diabetic and fatty rats at any time point studied (Table 1) .
Enhanced vasoconstriction found in the prediabetic arteriolar responses to NE were reversed following NOS inhibition, such that arterioles from control rats demonstrated increased vasoconstriction to NE relative to the prediabetic rats when preincubated in L-NAME (group difference: P < 0.01). Likewise, the augmented vasoconstriction found in the long-term diabetic rat arterioles compared to the agematched controls was abolished by NOS inhibition (group difference: P = 0.4). Neither the vasoconstrictor responsiveness (Fig 2C) nor the sensitivity to NE (EC 50 : PSS only,
M, P = 0.18) were altered by L-NAME in arterioles from pre-diabetic rats, whereas NOS inhibition in the arterioles from Control-7 rats resulted in a significant dose by treatment interaction resulting in increased vasoconstriction at given doses of NE (Fig 2A: NE [log M]: -9, -8, -7, -6: P < 0.01, -5: P Q 0.1) and an increased sensitivity to NE (EC 50 : PSS only, 0.4 E -8
M, P < 0.05). Similarly, NOS inhibition led to a significant dose by treatment interaction resulting in increased vasoconstriction in the arterioles of Control-20 rats at given NE doses (Fig 2B, NE [log M]: -8: P < 0.05, -7 & -6: P < 0.01), but did not alter the responses to NE in the long-term diabetic rats (Fig 2D) .
These data indicate that the modulator effect that NO has on NE-induced vasoconstriction under control conditions is ameliorated in arterioles from pre-diabetic and diabetic rats.
ET-1 Vasoconstriction. Similar to the NE response, there was a significant dose by group interaction resulting in increased vasoconstriction to given doses of ET-1 and an increased maximal vasoconstriction to ET-1 in the pre-diabetic gastrocnemius muscle arterioles ( Fig 3A, ET-1 [log M]: -8.5, -10.5: P Q 0.1, -8, -9, -9.5, -10: P Q 0.05). In the short-term diabetic rats, there was a greater sensitivity to ET-1 (EC 50 : Control-13: 6.2 E M, P < 0.05), although no dose by group interaction was found at this time point (Fig 3B) . Furthermore, no dose by group interaction, difference in maximal vasoconstriction or change in sensitivity to ET-1 was found during long-term diabetes (Fig 3C) . Sensitivity to ET-1 did not differ among age groups (7 wk vs. 13 wk vs. 20 wk) within either the pre-diabetic and diabetic groups or within the control groups.
To determine the influence of the NOS signaling pathway on ET-1 elicited vasoconstriction, ET-1 dose responses were repeated following NOS inhibition. These experiments were performed at time points that had previously demonstrated enhanced ET-1 vasoconstrictor reactivity, i.e., the pre-diabetic and short-term diabetic conditions. NOS inhibition increased tone in the gastrocnemius muscle arterioles from the prediabetic and short-term diabetic as well as their age-matched controls (Table 1 ).
Group differences occurring in the original dose-responses to ET-1 were abolished following incubation with L-NAME. Inhibition of NOS resulted in a trend (P Q 0.1) for greater maximal vasoconstriction of arterioles from control-7 rats (Fig 4A) , whereas inhibition of NOS resulted in greater vasoconstriction of arterioles from control-13 rats at all doses of ET-1 (Fig 4B, ET-1 [log M]: -11.5, -11, -10.5, -10, -9.5, -9, -8: P Q 0.01, -8.5: P < 0.05). Maximal vasoconstriction induced by ET-1 in arterioles from prediabetic ( Fig 4C) and short-term diabetic (Fig 4D) rats was unchanged by L-NAME.
These results suggests that the increases in sensitivity to NE and ET-1 that were originally found in the absence of L-NAME inhibition are an indirect effect of a decrease in NO bioavailability rather than a specific change in receptor sensitivity to the agonists.
KCl Vasoconstriction. In contrast to the NE and ET-1 responses, KCl-induced vasoconstriction was not different between Control-7 and pre-diabetic rats (Fig 5A) .
During short-term diabetes, maximal KCl-mediated vasoconstriction, but not sensitivity, was diminished in gastrocnemius muscle arterioles (Fig 5B KCl [mM] : 50, 80: P Q 0.1, 60, 100: P < 0.05), a time point at which no differences in NE-mediated and increased ET-1 mediated vasoconstriction were observed. Moreover, a significant dose by group interaction and resultant decreases in vasoconstriction to given doses of KCl were found during long-term diabetes (Fig 5C: KCl [mM] : 30, 40: P < 0.05). In addition, there was a decrease in sensitivity to KCl in the arterioles from the long-term diabetic rats (EC 50 :
Control-20: 29.6 ± 2.4 mM vs. long-term: 40.4 ± 3.3 mM, P Q 0.01) (Fig 5C) . There were no differences in EC 50 in the gastrocnemius muscle arterioles from diabetic rats across age groups, although sensitivity was higher in the Control-13 and Control-20 rats relative to Control-7 rats.
Arteriolar Mechanical Properties. Myogenic vasoconstriction was not altered in the pre-diabetic condition, although the passive distension of gastrocnemius muscle arterioles was greater at low intraluminal pressures (Fig 6A: mmHg: 0: P < 0.05, 11: P < 0.1). In short-term diabetic rats, no differences in the active myogenic response or passive distension occurred between groups (Fig 6B) . However, myogenic vasoconstrictor responsiveness was greater in the long-term diabetic rats (Fig 6C, group difference: P Q 0.01). Concurrent with this increase in active vasoconstriction to changes in intraluminal pressure, vessel passive distention was not different between the longterm diabetic rats and age-matched controls (Fig 6C) . Furthermore, examination of the passive mechanical properties of the arterial wall revealed no differences in incremental stiffness in the gastrocnemius muscle arterioles between pre-diabetic or diabetic rats and their age-matched controls (data not shown). M, P = 0.92) or dose by group interaction to ISO were found between the pre-diabetic and age-matched control rats. However, the maximal ISO-induced vasodilation (10 -6 M) was lower in pre-diabetes compared to agematched controls (Fig 7A, P < 0.05) . With short-term diabetes, these differences became more pronounced such that significant dose by group interactions resulting in reductions in vasodilation to given doses of ISO and a lower maximal vasodilation were found during both short-term (Fig 7B: ISO [log M]: -7, -6, -5: P < 0.05) and long-term diabetes (Fig 7C: ISO [log M ]: -7, -6, -5: P < 0.05). No differences in sensitivity to ISO were found during either short-term or long-term diabetes when compared to their respective age-matched controls.
Endothelium-dependent Vasodilation. Unlike that which was observed for ISO, there was no impairment of ACh-mediated vasodilation of arterioles from pre-diabetic and diabetic rats relative to age-matched controls (Table 3) . However, NOS inhibition with L-NAME indicated that although the dilator responses were preserved in prediabetic and diabetic arterioles, there was a diminished NO component to this vasodilation (Table 3 ). In the control rats, L-NAME significantly blunted ACh-mediated vasodilation at all time points examined. Although still significant, by 20 weeks of age the contribution of NO to ACh-induced vasodilation diminished from ~50% in Control-7 and Control-13 animals to ~30% in Control-20 rats; however, this reduction in the NO contribution across age failed to reach significance (P = 0.11). In ZDF rats, although there appears to be a reduction in the vasodilation to ACh with L-NAME blockade across the age groups, this difference failed to reach significance (P = 0.13). Despite the preserved maximal ACh-mediated dilation in the ZDF rats compared to their agematched controls, NO did not significantly contributed to ACh-induced vasodilation in the ZDF rat. This is in contrast to the control rats in which NO accounted for ~30-50% of the dilation in response to ACh.
Endothelium-independent Vasodilation. Maximal vasodilator responses to SNP
did not differ between Control-7 and pre-diabetic arterioles or between arterioles from short-term or long-term diabetic rats and their age-matched controls. Sensitivity to SNP was enhanced in the pre-diabetic arterioles, whereas no differences in arteriolar sensitivity to SNP were evident in short-term or long-term diabetes. Isotonic KCl, which elicits membrane hyperpolarization at 10 mM, did not result in any impairment of potential-mediated smooth muscle vasodilator responses in pre-diabetic and diabetic rats compared to age-matched controls (Table 3) .
eNOS and SOD-1 Protein Expression. The eNOS:GAPDH protein ratio (Control-7, 7.5 ± 3.6 vs. pre-diabetic, 6.4 ± 2.7; Control-13 wk, 3.5 ± 1.2 vs. short-term, 2.0 ± 1.4; Control-20, 1.0 ± 0.5 vs long-term, 0.6 ± 0.1) and the SOD-1:GAPDH protein ratio (Control-7, 7.5 ± 3.4 vs. pre-diabetic, 4.5 ± 1.2; Control-13, 2.7 ± 0.7 vs. short-term, 1.5 ± 0.7; Control-20, 1.8 ± 1.1 vs. long-term, 1.1 ± 0.2) were not different between groups at any age studied (n = 8-10/group).
Discussion
Microvascular reactivity has previously been shown to be related to both peripheral insulin sensitivity and blood pressure in normal healthy subjects (47) , so the emergence of a pro-constrictor phenotype in the microcirculation could be a significant contributor to the development of both overt diabetes and hypertension. Although a number of studies have examined vascular function in the metabolic syndrome (19-24, 40, 46, 52) , to our knowledge only one has examined changes in vascular function during a time course of type 2 diabetes (41), and none have done so in the skeletal muscle microcirculation or included a time point prior to the emergence of hyperglycemia.
Vascular research conducted using the OZR rat, a model of metabolic syndrome, may not be as specific to type 2 diabetes as a result of the extreme obesity of these animals. By 15 weeks of age the OZR rat has been reported to have almost doubled the body mass of their lean age-matched counterparts (~600 vs. ~350 g, respectively) (20, 23) . Because obesity is known to impair endothelial function independent of diabetes, it is impossible to separate the effects of obesity from those of diabetes in the OZR model.
In contrast, the body mass of the ZDF rat is slightly greater than their lean counterpart during prediabetes (~220 vs. ~170g, respectively), a time at which the rat is hyperinsulinemic but not yet hyperglycemic. With the onset of overt diabetes, body mass remains greater than that of controls (~360 vs. ~330g, respectively), but never reaches the same magnitude as that observed in the OZR animals, and at this time the ZDF rats are both hyperglycemic and hyperinsulinemic (short-term diabetes). Finally, as diabetes is sustained (long-term diabetes) there is no longer a difference in body mass between the ZDF and control rats (~410 vs. ~390 g, respectively). In fact, absolute body mass of the ZDF rat is lower than that of the lean age-matched controls, and the animals remain hyperglycemic but are no longer hyperinsulinemia. Thus, the present study was designed to take advantage of these known changes in glucose and insulin to examine vascular function at distinct time points in type 2 diabetes independent of the dramatic increases in body and fat mass observed in the OZR model.
In the present study, the data demonstrate that enhanced skeletal muscle arteriolar reactivity to NE and ET-1 occur prior to the onset of hypertension, and these alterations are largely due to reductions in NO signaling. Although a reduction in NO bioavailability has been previously shown in type 2 diabetes, a novel finding of the present study is that this reduction in NO signaling in the skeletal muscle vasculature precedes the development of overt diabetes and contributes to the enhanced vasoconstrictor responses in this vascular bed. With short-term diabetes, the onset of hypertension occurs concurrently with greater arteriolar sensitivity to ET-1 and KCl, whereas long-term diabetes and the concurrent hypertension are associated with enhanced NE and myogenic vasoconstriction in skeletal muscle arterioles. Furthermore, during pre-diabetes and each stage in the progression of diabetes there is diminished Fadrenergic vasodilation.
The ZDF rat exhibits a period of insulin resistance at 7 wk of age (8, 17, 18, 25, 42 , 50, 51, 57), a condition referred to as pre-diabetes, such that there is a significant decrease in glucose uptake in isolated skeletal muscles (17) . During this pre-diabetic condition, normal fasted blood glucose and elevated plasma insulin are being manifest (Table 1) . At approximately 10-12 weeks of age a transition to overt diabetes occurs with the development of marked hyperglycemia (Table 1 ). In the present study, we demonstrate that the development of overt diabetes is also associated with the emergence of hypertension. As a result, the vasculature of this rat model is exposed to a changing chemical milieu and mechanical environment that have the potential to alter vasomotor responsiveness. Thus, with the onset of overt short-term diabetes, the chemical environment of the arterioles has progressed from one of transient postprandial hyperglycemia in the face of chronic hyperinsulinemia to one of marked chronic hyperglycemia and hyperinsulinemia. With the further progression of long-term diabetes, the ZDF rat can be characterized as being hyperglycemic and hypoinsulinemic (Table 1) .
As changes in both plasma glucose (33, 34) and insulin (43) concentration have been shown to affect vascular function, these divergent factors may contribute to differential alterations in vascular responsiveness. This progression is in contrast to the OZR rat which remains hyperinsulinemic throughout at least 32 weeks of age and is a model representative of metabolic syndrome and not type 2 diabetes per se (41) .
Increased responsiveness to the vasoconstrictor effects of both NE (Fig 1A) and ET-1 (Fig 3A) , as well as reduced F-adrenergic-mediated vasodilation (Fig 7A) , occur prior to the onset of diabetes in arterioles from the gastrocnemius, a skeletal muscle composed predominantly of fast-twitch fibers (10) . The resultant effect of this proconstrictor phenotype in arterioles from fast-twitch skeletal muscle of prediabetic rats is potentially significant, since fast-twitch low-oxidative muscle accounts for approximately 70% of the total skeletal muscle mass in the rat (10), and skeletal muscle as a whole receives approximately 18% of the total cardiac output at rest (12) . Therefore, an increase in vasoconstrictor tone in this muscle type could contribute significantly to the development of hypertension and insulin resistance. Furthermore, previous investigations have reported that both sympathetic nerve activity (16) and plasma ET -1 concentration (13) are increased in obesity. If these observations are applicable to ZDF rats, enhanced vasoconstrictor responsiveness in the face of increased sympathetic drive and elevated ET-1 concentrations would act to further exacerbate vasoconstrictor tone, increases in blood pressure, and insulin resistance.
In the present study there are no alterations in maximal vasodilator responses to ACh, 10 mM KCl, and SNP, whereas adrenergic-mediated vasodilation is diminished.
This suggests that there may be F 2-receptor-specific defects in vasodilator function rather than a generalized defect in vasodilator capacity that occurs in conjunction with increases in vasoconstriction. Interestingly, the increases in vasoconstriction observed in the present study appear to result from decrements in NO bioavailability (Fig 2&4) , which is consistent with the ACh responses where the contribution of NO to the vasodilator responses was diminished in prediabetic and diabetic rats. In response to ACh administration, however, it appears that other vasodilator substances, such as endothelium derived hyperpolarizing factors or prostanoid dilators, are able to compensate for the reduction in NO bioavailability. Thus, our data demonstrate that reduced nitric oxide-mediated vasodilation opposing the adrenergic and ET-1 mediated vasoconstriction leads to a net increase vasoconstriction that may be further exacerbated by reductions in adrenergic vasodilator responses. The resultant effect of these two influences would be a pro-constrictor phenotype in the skeletal muscle arterioles of the prediabetic and diabetic rats.
Although an NO-mediated mechanism for isoproterenol-induced vasodilation has been described using venous occlusion plethysmography in humans (44), studies from our laboratory (14) and others (35) have demonstrated that isoproterenol induces vasodilation in an endothelium-and NO-independent manner in both rat skeletal muscle and coronary arterioles, respectively. The diminished adrenergic vasodilation could result from a generalized smooth muscle vasodilator dysfunction, but this does not appear to be the case since ACh, SNP and KCl-mediated vasodilation were preserved in these arterioles. Given that F-adrenergic receptor-mediated vasodilation to isoproterenol occurs through the activation of the voltage gated potassium channels and the activation of adenylate cyclase (35) , whereas nitric oxide induced vasodilation occurs predominately through cGMP-mediated reductions in intracellular calcium (56) , these data suggest that there may be a specific defect in adrenergic signaling through cAMP.
The diminished NO counter-influence to the NE and ET-1 vasoconstrictor responses are consistent with the notion of diminished NO bioavailability in this model and are further supported by the reduction in NO-mediated dilation in response to stimulation by ACh (Table 3) . Reduced substrate or cofactors (e.g., L-arginine, BH 4 ) and increases in reactive oxygen species could contribute to a loss of NO bioavailability. suggested that reactive oxygen species may indeed play a role in reducing the activity of NO in these rats. To determine whether a reduction in either the enzyme responsible for NO production, eNOS, or a decrease in the free radical scavenger, SOD-1, is associated with the altered NOS signaling mechanism, we measured gastrocnemius muscle arteriolar protein content of these enzymes. However, we found no differences in protein expression for either enzyme, suggesting that the quantity of these proteins is not affecting NO signaling. However, the possibility remains that enzyme activity and not protein content per se is being altered in the prediabetic and diabetic conditions, a possibility that requires further elucidation.
In conclusion, the present study examined changes in vascular function resulting from type 2 diabetes at time points that are distinct in the progression of this disease. The skeletal muscle microvasculature was chosen because of its large contribution to both glucose uptake and peripheral resistance, and first-order arterioles from the gastrocnemius muscle were selected to represent the resistance vasculature in fast skeletal muscle tissue. The present study expands current knowledge by including an examination of the time-course of both the changes in vascular function and the emergence of hypertension in the ZDF model. In this skeletal muscle arteriole, increased vasoconstrictor responses to NE and ET-1 in pre-diabetes are mediated through a decrement in the counter influence of the NOS signaling mechanism. This enhanced vasoconstriction, combined with diminished -adrenergic vasodilation, could contribute to the later increases in mean arterial pressure and further deterioration of insulin sensitivity. Our current working model suggests that an early augmentation in adrenergic and ET-1 mediated vasoconstriction contribute to the coordinated emergence of hypertension and diabetes. The enhancement in vasoconstrictor responsiveness in this prediabetic state may result from increases in sympathetic nervous system activity (16), circulating ET-1 (13), and increased plasma insulin (45) . However, in long-term diabetes prolonged exposure to these agonists augments myogenic vasoconstriction, which may act to maintain the increases in blood pressure even in the face of adrenergic and ET-1 receptor desensitization (Fig 1 & 3) . Furthermore, these results suggest that interventions aimed at increasing NO bioavailability during the prediabetic state may serve to combat the hypertension associated with the onset of type 2 diabetes. Table 1 . Animal, muscle and arteriolar characteristics from in vitro studies of prediabetic (PRE), short-term (ST) and long-term (LT) diabetic ZDF:(fa/fa) and lean ZDF:(+/?) age-matched control (CNT-7, CNT-13, CNT-20, respectively) rats. Table 3 . Maximal responses (Max) and concentrations eliciting a half maximal response (IC 50 ) to acetylcholine, in the absence and presence of the NOS inhibitor L-NAME, sodium nitroprusside (SNP) and KCl in gastrocnemius muscle arterioles from prediabetic (PRE), short-term (ST) and long-term (LT) diabetic and age-matched control (CNT-7, CNT-13, and CNT-20, respectively) rats. 
Concentration-response relations to isotonic KCl in gastrocnemius muscle
arterioles from (A) prediabetic, (B) short-term diabetic, and (C) long-term diabetic ZDF rats compared to age-matched controls (n = 9-11/group). * Denotes significant group by dose interaction for the dose-response relations; † denotes significant differences in maximal responses (P < 0.05). Values are means ± SEM.
Figure 6
Active (n = 8-10/group) and passive (n = 11-13/group) pressure diameter relations of gastrocnemius muscle arterioles in (A) prediabetic, (B) shortterm diabetic, and (C) long-term diabetic ZDF rats. * Denotes significant
